Skip to main content

Advertisement

SpringerLink
Log in

Comparative Activity of Chlonisol and Temozolomide in Mice After Intracranial Transplantation of Ehrlich Carcinoma and HER2-Positive Breast Cancer

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

In continuation of a preclinical study of the new alkylating anticancer drug chlonisol {2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol} created by us, its activity was assessed after intracranial transplantation of Ehrlich carcinoma and HER2-positive breast cancer into mice. Temozolomide, which is used in the treatment of malignant gliomas, was selected as an alkylating reference drug. Chlonisol significantly increased the median lifespan of tumor-bearing animals, surpassing temozolomide in activity for both tumor models. A comparison of survival curves of mice with HER2-positive breast cancer tumor transplants revealed no therapeutic effect of temozolomide, unlike an obvious increase in the survival of mice in the chlonisol group. Chlonisol can be a potential cytostatic agent in the chemotherapy of neoplastic lesions of the nervous system, which is extremely important in the treatment of HER2-positive breast cancer, which often metastasizes to the brain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. A. N. Stukov, K. A. Esikov, L. M. Usmanova, et al., Khim.-farm. Zh., 54(6), 35 – 38 (2020); Pharm. Chem. J., 54(6), 579 – 581 (2020).

  2. A. N. Stukov, S. F. Vershinina, N. N. Kharitonova, et al., Toksikol. Vestn., 165(6), 49 – 53 (2020).

    Article  Google Scholar 

  3. L. A. Ostrovskaya, V. A. Filov, B. A. Ivin, et al., Ross. Bioterapevticheskii Zh., 3(1), 37 – 48 (2004).

    Google Scholar 

  4. Ya. G. Murazov, A. N. Stukov, Yu. G. Zmitrichenko, et al., Farmakokinet. Farmakodin., 1, 23 – 29 (2021).

    Google Scholar 

  5. W. Cruz-Munoz and R. S. Kerbel, Semin. Cancer Biol., 21(2), 123 – 130 (2011).

    Article  Google Scholar 

  6. J. Chua, E. Nafziger, and D. Leung, Curr. Oncol. Rep., 21(4), 30 (2019).

    Article  Google Scholar 

  7. S. Pernas and S. M. Tolaney, Ther. Adv. Med. Oncol., 11, 1 – 16, 1758835919833519 (2019).

  8. V. N. Anisimov, P. A. Egormin, T. S. Piskunova, et al., Cell Cycle, 9(1), 188 – 197 (2010).

    Article  CAS  Google Scholar 

  9. A. N. Stukov, L. V. Filatova, D. Kh. Latipova, et al. Vopr. Onkol., 61(2), 274 – 279 (2015).

    CAS  Google Scholar 

  10. J. Wang and B. Xu, Signal Transduction Targeted Ther., 4, 34 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 68 Leningradskaya St, St. Petersburg, 197758, Russia

    V. A. Alexandrov, A. N. Stukov, Yu. G. Zmitrichenko & G. V. Tochilnikov

Authors
  1. V. A. Alexandrov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. N. Stukov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu. G. Zmitrichenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. V. Tochilnikov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. A. Alexandrov.

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 56, No. 9, pp. 24 – 27, September, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alexandrov, V.A., Stukov, A.N., Zmitrichenko, Y.G. et al. Comparative Activity of Chlonisol and Temozolomide in Mice After Intracranial Transplantation of Ehrlich Carcinoma and HER2-Positive Breast Cancer. Pharm Chem J 56, 1179–1182 (2022). https://doi.org/10.1007/s11094-022-02773-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-022-02773-1

Keywords

Search

Navigation